Drug Profile


Alternative Names: ALD 518; ALD518-003; BMS-645429; BMS-945429

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alder Biopharmaceuticals
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Psoriatic arthritis; Rheumatoid arthritis
  • Suspended Anaemia; Cachexia; Fatigue; Stomatitis
  • No development reported Crohn's disease; Graft-versus-host disease

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 06 May 2016 Clazakizumab licensed to Vitaeris worldwide
  • 23 Feb 2016 Alder Biopharmaceuticals has patent protection for clazakizumab in USA (Alder Biopharmaceuticals, Form 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top